Assignee
DICERNA PHARMACEUTICALS INC
US·96 granted patents·44 pending applications·499 citations·filing 2009–2025
Top patents by PatentIndex Score
140 records- 0199US8927705B2Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2012·Granted Jan 6, 2015·83 cites·46 claims
- 0298US8349809B2Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2010·Granted Jan 8, 2013·162 cites·102 claims
- 0396US10370655B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2016·Granted Aug 6, 2019·14 cites·22 claims
- 0496US10144725B2Amine cationic lipids and uses thereofDICERNA PHARMACEUTICALS INC·Filed 2017·Granted Dec 4, 2018·21 cites·25 claims
- 0596US9458457B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Oct 4, 2016·19 cites·52 claims
- 0695US11359198B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Jun 14, 2022·2 cites·23 claims
- 0794US10870849B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2014·Granted Dec 22, 2020·7 cites·63 claims
- 0894US10131912B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2014·Granted Nov 20, 2018·15 cites·8 claims
- 0994US8372816B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2010·Granted Feb 12, 2013·12 cites·57 claims
- 1093US12077756B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2022·Granted Sep 3, 2024·1 cites·22 claims
- 1193US11661604B2Methods and compositions for inhibiting expression of LDHADICERNA PHARMACEUTICALS INC·Filed 2020·Granted May 30, 2023·3 cites·20 claims
- 1293US10036017B2Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2016·Granted Jul 31, 2018·5 cites·24 claims
- 1393US9701966B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Jul 11, 2017·12 cites·68 claims
- 1492US11597929B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Mar 7, 2023·1 cites·20 claims
- 1592US11052104B2Methods for treating hepatitis B infectionDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Jul 6, 2021·3 cites·20 claims
- 1692US10837013B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2014·Granted Nov 17, 2020·5 cites·63 claims
- 1792US10351854B2Therapeutic inhibition of lactate dehydrogenase and agents thereforDICERNA PHARMACEUTICALS INC·Filed 2015·Granted Jul 16, 2019·9 cites·34 claims
- 1892US10150965B2Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Dec 11, 2018·6 cites·24 claims
- 1992US9828606B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2017·Granted Nov 28, 2017·7 cites·38 claims
- 2092US8815825B2Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2012·Granted Aug 26, 2014·12 cites·45 claims
- 2191US11414664B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Aug 16, 2022·1 cites·20 claims
- 2291US11408003B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Aug 9, 2022·1 cites·23 claims
- 2391US11060093B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Jul 13, 2021·2 cites·20 claims
- 2491US10752899B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2017·Granted Aug 25, 2020·3 cites·31 claims
- 2591US10676742B2Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Jun 9, 2020·3 cites·30 claims
- 2691US9200284B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2013·Granted Dec 1, 2015·5 cites·53 claims
- 2790US11053502B1Therapeutic inhibition of lactate dehydrogenase and agents thereforDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Jul 6, 2021·2 cites·30 claims
- 2890US10738311B2Therapeutic inhibition of lactate dehydrogenase and agents thereforDICERNA PHARMACEUTICALS INC·Filed 2019·Granted Aug 11, 2020·3 cites·39 claims
- 2989US11773390B2Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2020·Granted Oct 3, 2023·1 cites·20 claims
- 3088US11634713B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Apr 25, 2023·1 cites·32 claims
- 3188US10954517B2Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Mar 23, 2021·2 cites·20 claims
- 3288US9809819B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Nov 7, 2017·6 cites·26 claims
- 3388US8927515B2Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2012·Granted Jan 6, 2015·9 cites·42 claims
- 3487US12252691B2Compositions and methods for inhibiting LPA expressionDICERNA PHARMACEUTICALS INC·Filed 2024·Granted Mar 18, 2025·0 cites·4 claims
- 3587US11447777B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2020·Granted Sep 20, 2022·1 cites·27 claims
- 3687US10799524B2Methods for treating hepatitis B infectionDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Oct 13, 2020·2 cites·21 claims
- 3787US10675295B2Compositions and methods for inhibiting HMGB1 expressionDICERNA PHARMACEUTICALS INC·Filed 2018·Granted Jun 9, 2020·5 cites·20 claims
- 3887US10435692B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2017·Granted Oct 8, 2019·3 cites·20 claims
- 3986US11414659B24'-phosphate analogs and oligonucleotides comprising the sameDICERNA PHARMACEUTICALS INC·Filed 2017·Granted Aug 16, 2022·3 cites·44 claims
- 4086US11273173B2Methods for treating hepatitis B infectionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Mar 15, 2022·1 cites·30 claims
- 4186US9732347B2Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Aug 15, 2017·6 cites·38 claims
- 4285US10689647B2Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2016·Granted Jun 23, 2020·2 cites·32 claims
- 4385US10612023B2Methods and compositions for the specific inhibition of β-catenin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Apr 7, 2020·1 cites·21 claims
- 4485US10487330B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Nov 26, 2019·2 cites·30 claims
- 4585US10465195B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Nov 5, 2019·2 cites·28 claims
- 4685US9217146B2Phase changing formulations of nucleic acid payloadsDICERNA PHARMACEUTICALS INC·Filed 2013·Granted Dec 22, 2015·4 cites·20 claims
- 4784US11851658B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2022·Granted Dec 26, 2023·0 cites·17 claims
- 4883US11912996B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2022·Granted Feb 27, 2024·0 cites·24 claims
- 4983US9549983B2Amine cationic lipids and uses thereofDICERNA PHARMACEUTICALS INC·Filed 2014·Granted Jan 24, 2017·4 cites·31 claims
- 5082US11052105B2Methods for treating hepatitis B infectionDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Jul 6, 2021·1 cites·27 claims
Showing the top 50 of 140 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →